Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Brentuximab (Adcetris) for Hodgkin’s Lymphoma (post-ASCT) Resubmission 
(Final Recommendation Issued as of February 21, 2018)

Fulvestrant (Faslodex) for Locally Advanced or Metastatic Breast Cancer 
(Notification to Implement Issued as of February 16, 2018)

Obinutuzumab (Gazyva) for Follicular Lymphoma (previously untreated)
(Pending Submission as of February 14, 2018)

Cetuximab (Erbitux) for Left Sided Metastatic Colorectal Carcinoma 
(Pending Submission as of December 13, 2017)


Find a Drug Review